Overall, our study indicates that CKB downregulation is associated with poor prognosis in prostate cancer, and CKB downregulation functionally promotes prostate cancer progression, at least in part by promoting AKT activation and EMT. The gene discussed is AKT1; the disease is prostate carcinoma.